Perioperative and periprocedural management of GLP-1 receptor-based agonists and SGLT2 inhibitors: narrative review and the STOP-GAP and STOP DKA-2 algorithms
Current Medical Research and Opinion,
Journal Year:
2025,
Volume and Issue:
unknown, P. 1 - 17
Published: Jan. 28, 2025
The
GLP-1
receptor-based
agonists
(GLP-1RAs)
and
SGLT2
inhibitors
(SGLT2i)
are
major
twenty
first
century
breakthroughs
in
diabetes
obesity
medicine
but
there
important
safety
considerations
regarding
the
perioperative
periprocedural
management
of
individuals
who
treated
with
these
agents.
GLP-1RAs
have
been
linked
to
an
increased
risk
retained
gastric
contents
pulmonary
aspiration
while
SGLT2i
can
be
associated
diabetic
ketoacidosis.
This
manuscript
provides
a
narrative
review
available
evidence
for
risks
people
prescribed
SGLT2i.
authors
provide
expert
opinion-driven
recommendations
algorithms
on
how
safely
manage
under
perioperative/periprocedural
settings.
Language: Английский
Anti-obesity drugs for the gastroenterologists
Frontline Gastroenterology,
Journal Year:
2025,
Volume and Issue:
unknown, P. flgastro - 102995
Published: March 3, 2025
Glucagon-like
peptide-1
receptor
agonists
(GLP-1RAs)
are
increasingly
used
in
the
management
of
diabetes
mellitus
and
obesity
have
become
accessible
to
many
through
non-standard
prescribing
pathways.
Studies
demonstrating
a
plethora
positive
effects
on
cardiovascular
health,
renal
disease
liver
disease,
which
may
be
directly
related
mitigation
or
obesity-associated
risks
these
complications
possibly
direct
protective
effects.
However,
agents
slow
gastrointestinal
motility,
can
lead
side
increased
gastro-oesophageal
reflux,
nausea,
vomiting,
constipation
paradoxical
diarrhoea.
More
severe
adverse
include
cholelithiasis,
acute
pancreatitis
risk
medullary
cell
thyroid
cancer.
Gastroenterologists
being
consulted
for
effects,
discussion
around
best
symptoms
is
presented.
Safety
endoscopic
procedures
has
also
been
subject
much
discussion,
latest
guidance
outlined
endoscopists.
Language: Английский
The impact of glucagon-like peptide-1 receptor agonists on the quality indicators of colonoscopy – a systematic review and meta-analysis
Digestive and Liver Disease,
Journal Year:
2025,
Volume and Issue:
unknown
Published: March 1, 2025
Language: Английский
Colonoscopy preparation adequacy in glucagon-like peptide-1 receptor agonist users: the jury is still out
Carol A. Burke,
No information about this author
Harish K. Gagneja
No information about this author
Endoscopy,
Journal Year:
2024,
Volume and Issue:
unknown
Published: Nov. 22, 2024
Colonoscopy
is
a
common
procedure.
In
2013
an
estimated
14
million
colonoscopies
were
performed
in
the
USA,
with
80%
for
colorectal
cancer
screening
[1].
The
effectiveness,
accuracy,
and
safety
of
colonoscopy
incumbent
on
variety
factors
codified
by
professional
organizations
as
key
performance
indicators.
It
recommended
that
adequate
bowel
preparation,
one
most
important
quality
metrics,
attained
≥90%
patients,
this
endorsed
both
European
US
guidelines
[2]
[3].
Inadequate
preparation
(IBP)
has
been
demonstrated
15
%–35
%
varies
medical
setting
patient
population,
ultimately
negatively
impacting
other
metrics
including
adenoma
detection
cecal
intubation
rates,
while
lengthening
procedure
time,
reducing
surveillance
intervals,
increasing
costs.
A
few
known
associated
IBP
include
diabetes,
obesity,
gastroparesis
motility
disorders,
constipation,
medications
such
anticholinergics,
angiotensin
converting
enzyme
inhibitors,
calcium
channel
receptor
blockers,
tricyclic
antidepressants,
opiates,
to
name
few.
Language: Английский